Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUTLNASDAQ:CDTXNASDAQ:ERYPNASDAQ:HUMA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUTLAutolus Therapeutics$1.54+0.7%$1.42$1.11▼$5.00$409.86M1.771.49 million shs1.15 million shsCDTXCidara Therapeutics$24.28-5.5%$20.72$10.14▼$28.42$304.64M0.8678,419 shs163,459 shsERYPERYTECH Pharma$3.10$4.66$0.30▼$1.47$105.77M2.6993,510 shsN/AHUMAHumacyte$2.53+5.4%$1.77$1.15▼$9.97$392.45M1.643.78 million shs3.76 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUTLAutolus Therapeutics+0.65%+15.79%+1.99%-21.03%-59.90%CDTXCidara Therapeutics-5.53%-4.78%+10.87%+13.09%+96.76%ERYPERYTECH Pharma0.00%0.00%0.00%0.00%0.00%HUMAHumacyte+5.42%+12.95%+72.11%-28.63%-66.53%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAUTLAutolus Therapeutics3.3845 of 5 stars3.54.00.00.03.33.30.6CDTXCidara Therapeutics4.384 of 5 stars4.64.00.04.62.10.80.0ERYPERYTECH PharmaN/AN/AN/AN/AN/AN/AN/AN/AHUMAHumacyte2.5253 of 5 stars3.52.00.00.02.82.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUTLAutolus Therapeutics 3.00Buy$9.32505.19% UpsideCDTXCidara Therapeutics 3.22Buy$41.8672.39% UpsideERYPERYTECH Pharma 0.00N/AN/AN/AHUMAHumacyte 3.00Buy$11.71363.02% UpsideCurrent Analyst Ratings BreakdownLatest ERYP, AUTL, HUMA, and CDTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/23/2025CDTXCidara TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$31.00 ➝ $35.005/23/2025CDTXCidara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.005/16/2025CDTXCidara TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$35.00 ➝ $50.005/14/2025HUMAHumacyteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$4.005/14/2025HUMAHumacyteBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $14.005/13/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.005/9/2025CDTXCidara TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$33.00 ➝ $35.005/9/2025CDTXCidara TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$46.00 ➝ $47.004/29/2025CDTXCidara TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$46.00 ➝ $46.004/10/2025AUTLAutolus TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/10/2025CDTXCidara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.00 ➝ $35.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUTLAutolus Therapeutics$9.01M45.48N/AN/A$0.64 per share2.41CDTXCidara Therapeutics$302K1,008.75N/AN/A($1.82) per share-13.34ERYPERYTECH Pharma$32.66M3.24N/AN/A$0.80 per share3.88HUMAHumacyte$517K759.09N/AN/A$0.13 per share19.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUTLAutolus Therapeutics-$208.38M-$0.88N/AN/AN/AN/A-63.65%-36.54%N/ACDTXCidara Therapeutics-$22.93M-$29.47N/AN/AN/A-289.05%-69.64%-33.73%8/11/2025 (Estimated)ERYPERYTECH Pharma-$240KN/A0.00∞N/AN/AN/AN/AN/AHUMAHumacyte-$110.78M-$0.69N/AN/AN/AN/A-942.81%-93.82%8/12/2025 (Estimated)Latest ERYP, AUTL, HUMA, and CDTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025HUMAHumacyte-$0.19-$0.10+$0.09$0.28$0.46 million$0.52 million5/8/2025Q1 2025AUTLAutolus Therapeutics-$0.24-$0.26-$0.02-$0.26$1.59 million$8.98 million5/8/2025Q1 2025CDTXCidara Therapeutics-$5.45-$1.66+$3.79-$1.66N/AN/A3/28/2025Q4 2024HUMAHumacyte-$0.23-$0.16+$0.07-$0.16$0.64 million$7.23 million3/20/2025Q4 2024AUTLAutolus Therapeutics-$0.21-$0.09+$0.12-$0.09$2.98 million$0.03 million3/6/2025Q4 2024CDTXCidara Therapeutics-$5.28-$5.38-$0.10-$5.37N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUTLAutolus TherapeuticsN/AN/AN/AN/AN/ACDTXCidara TherapeuticsN/AN/AN/AN/AN/AERYPERYTECH PharmaN/AN/AN/AN/AN/AHUMAHumacyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUTLAutolus TherapeuticsN/A13.6913.69CDTXCidara TherapeuticsN/A3.543.54ERYPERYTECH Pharma0.323.653.65HUMAHumacyteN/A1.101.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUTLAutolus Therapeutics72.83%CDTXCidara Therapeutics35.82%ERYPERYTECH Pharma1.09%HUMAHumacyte44.71%Insider OwnershipCompanyInsider OwnershipAUTLAutolus Therapeutics25.70%CDTXCidara Therapeutics3.89%ERYPERYTECH Pharma1.94%HUMAHumacyte5.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUTLAutolus Therapeutics330266.14 million197.71 millionOptionableCDTXCidara Therapeutics9012.55 million6.51 millionNo DataERYPERYTECH Pharma4934.12 million33.46 millionNot OptionableHUMAHumacyte150155.12 million111.76 millionOptionableERYP, AUTL, HUMA, and CDTX HeadlinesRecent News About These CompaniesWoodline Partners LP Has $14.39 Million Holdings in Humacyte, Inc. (NASDAQ:HUMA)May 24 at 5:02 AM | marketbeat.comHumacyte, Inc. (NASDAQ:HUMA) Given Average Rating of "Buy" by AnalystsMay 20, 2025 | marketbeat.comQ3 Earnings Estimate for Humacyte Issued By HC WainwrightMay 20, 2025 | marketbeat.comHumacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NasdaqMay 19, 2025 | globenewswire.comBenchmark Lowers Humacyte (NASDAQ:HUMA) Price Target to $14.00May 17, 2025 | americanbankingnews.comWhat is HC Wainwright's Estimate for Humacyte Q2 Earnings?May 17, 2025 | americanbankingnews.comHumacyte (NASDAQ:HUMA) Coverage Initiated by Analysts at HC WainwrightMay 16, 2025 | americanbankingnews.comHumacyte (NASDAQ:HUMA) Earns "Buy" Rating from D. Boral CapitalMay 15, 2025 | marketbeat.comHumacyte (NASDAQ:HUMA) Earns Buy Rating from D. Boral CapitalMay 15, 2025 | americanbankingnews.comEarnings call transcript: Humacyte Q1 2025 beats EPS forecast, stock surgesMay 14, 2025 | investing.comDurham firm with battered stock cuts jobs to save cashMay 14, 2025 | bizjournals.comHumacyte, Inc. (NASDAQ:HUMA) Q1 2025 Earnings Call TranscriptMay 14, 2025 | msn.comQ1 2025 Humacyte Inc Earnings CallMay 14, 2025 | finance.yahoo.comHumacyte outlines expansion of Symvess to 45 hospitals while targeting BLA submission for ATEV in dialysis by 2026May 14, 2025 | msn.comHumacyte, Inc. (HUMA) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comHumacyte, Inc. (HUMA) Reports Q1 Loss, Lags Revenue EstimatesMay 13, 2025 | zacks.comHumacyte Announces First Quarter 2025 Financial Results and Provides Business UpdateMay 13, 2025 | globenewswire.comHumacyte Q1 2025 Earnings PreviewMay 12, 2025 | msn.comExploring Humacyte's Earnings ExpectationsMay 12, 2025 | benzinga.comHumacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025May 9, 2025 | globenewswire.comBrevan Howard Capital Management LP Boosts Stake in Humacyte, Inc. (NASDAQ:HUMA)May 8, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongWhy D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumNVIDIA Stock Surges on Bullish News: How High Could It Climb?By Thomas Hughes | May 13, 2025View NVIDIA Stock Surges on Bullish News: How High Could It Climb?AMD’s AI-Powered Stock Price Rally Just Shifted GearsBy Thomas Hughes | May 14, 2025View AMD’s AI-Powered Stock Price Rally Just Shifted GearsERYP, AUTL, HUMA, and CDTX Company DescriptionsAutolus Therapeutics NASDAQ:AUTL$1.54 +0.01 (+0.65%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.52 -0.03 (-1.62%) As of 05/23/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.Cidara Therapeutics NASDAQ:CDTX$24.28 -1.42 (-5.53%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$24.35 +0.07 (+0.29%) As of 05/23/2025 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.ERYTECH Pharma NASDAQ:ERYPERYTECH Pharma S.A., a biopharmaceutical company, focus on development of red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. ERYTECH Pharma S.A. was incorporated in 2004 and is headquartered in Lyon, France.Humacyte NASDAQ:HUMA$2.53 +0.13 (+5.42%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$2.52 -0.01 (-0.40%) As of 05/23/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
